Menlo Park rare lung condition startup lands big deal with Italian biopharma
A small Menlo Park startup focused on a drug-device to treat a condition that arises in some lung and stem cell transplant patients scored a potential half-billion-dollar buyout by an Italy-based drug company.
Breath Therapeutics Inc., which also has offices and labs in Munich, Germany, will receive an initial $156 million — or 140 million euros — so Zambon S.p.A. can get control of an inhaled form of a common transplant rejection drug and the nebulizer that delivers it. The ultimate payout…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Germany Health | Health Management | Italy Health | Lung Transplant | Men | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants